Nuti Francesca, Paolini Ilaria, Cardona Francesca, Chelli Mario, Lolli Francesco, Brandi Alberto, Goti Andrea, Rovero Paolo, Papini Anna M
Laboratory of Peptide & Protein Chemistry & Biology, Polo Scientifico e Tecnologico, University of Florence, I-50019 Sesto Fiorentino (FI), Italy.
Bioorg Med Chem. 2007 Jun 15;15(12):3965-73. doi: 10.1016/j.bmc.2007.04.007. Epub 2007 Apr 10.
CSF114(Glc) is the first synthetic Multiple Sclerosis Antigenic Probe able to identify autoantibodies in a statistically significant number of Multiple Sclerosis patients. The beta-turn conformation of this glucopeptide is fundamental for a correct presentation of the epitope Asn(Glc). To verify the influence of sugar mimics in antibody recognition in Multiple Sclerosis, we synthesized Fmoc-protected Asn derivatives containing alkaloid-type sugar mimics. The corresponding glycomimetics-containing peptide derivatives of the CSF114-type sequence were tested in competitive and solid-phase non-competitive ELISA on Multiple Sclerosis patients' sera.
CSF114(Glc)是首个能够在统计学上显著数量的多发性硬化症患者中识别自身抗体的合成多发性硬化症抗原探针。这种糖肽的β-转角构象对于表位Asn(Glc)的正确呈现至关重要。为了验证糖类模拟物对多发性硬化症中抗体识别的影响，我们合成了含有生物碱型糖类模拟物的Fmoc保护的天冬酰胺衍生物。在针对多发性硬化症患者血清的竞争性和固相非竞争性酶联免疫吸附测定中，对CSF114型序列的相应含糖类模拟物的肽衍生物进行了测试。
